DocWire News Editors

DocwireNews

Patients with treatment-na&iuml;ve Waldenstr&ouml;m macroglobulinemia (WM) who receive frontline immunochemotherapy have excellent outcomes that can be achieved with a finite course of therapy, according to the findings of a study conducted by Jowon Laura Kim, MD, and colleagues. Results were presented at the 2021 American Society of Hematology Annual Meeting.Researchers used the BC Cancer Centre for Lymphoid Cancer Database to assess 111 patients with previously untreated WM (median age = 69 years) who were treated with bendamustine-rituximab (BR) (n = 57) or R-CVP chemotherapy (n = 54) as frontline therapy between August 2004 and August 2020. For inclusion, patients were required to have clinicopathologically confirmed lymphoplasmacytic lymphoma and measurable monoclonal IgM.&nbsp;The outcomes of interest were event-free survival (EFS), defined as time from start of immunochemotherapy to progression, relapse, initiation of alternative therapy, histologic transformation, or death due to any cause, and early progression (POD24; defined as relapse or progression, death from lymphoma, or treatment toxicity within 24 months of initiation of systemic therapy). These outcomes were compared with a historical cohort of patients treated with frontline R-CVP.According to the results, a higher proportion of R-CVP-treated patients received four or more cycles of chemotherapy (81% vs. 65%; p = 0.049). Following immunochemotherapy, 68% received maintenance rituximab, with 63% and 72% in the BR and R-CVP groups, respectively (p = 0.3). The researchers noted that EFS was established at 6.3 years for R-CVP due to longer duration of follow-up. Overall survival (OS) estimates at 4 years were found to be robust, at 74% and 81% for BR and R-CVP, respectively (p = 0.6). A sub-analysis of only patients administered at least cycles of immunochemotherapy also showed no clear difference in outcomes between BR and R-CVP.Furthermore, the median time to transformation was 6.5 years, with only three late biopsy-proven events, according to the researchers. POD24 occurred in 18% of patients, with inferior survival observed in patients who had an early event compared with a reference cohort; however, the researchers stated, this observation did not reach statistical significance (p = 0.3)&ldquo;This population-based analysis of treatment-na&iuml;ve WM patients treated with upfront immunochemotherapy confirms the excellent outcomes that can be achieved with a finite course of therapy,&rdquo; the researchers concluded. &ldquo;In contrast to prior studies, similar outcomes were observed with R-CVP and BR. Further, regardless of frontline therapy, POD24 may be associated with inferior outcome but larger studies are needed.&rdquo;

Jordana Jampel

Positive Preliminary Results From Phase 1 Trial of Dopaminergic Neuron Graft for Parkinson’s Disease

Dementia

Bradley Warady, MD

Joel M. Topf, MD, FACP

2025 Hume Award Winner Is Dedicated to Children’s Care

NKF Spring Clinical Meetings 2025

Distant Brain Metastases in Cutaneous Melanoma May Be Mitigated With Multiple Pathway Inhibitors

Melanoma

Latest News

Assessing Frontline Therapy with Bendamustine-Rituximab in Patients with Treatment-Naïve Waldenstrom Macroglobulinemia

ASH Annual Meeting and Exposition 2021

Patients with treatment-naïve Waldenström macroglobulinemia (WM) who receive frontline immunochemotherapy have excellent outcomes that can be achieved with a finite course ...

Assessing Frontline Therapy with Bendamustine-Rituximab in Patients with Treatment-Naïve

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe